Kura Oncology (KURA) Accumulated Expenses (2010 - 2026)
Kura Oncology (KURA) reported Accumulated Expenses of $10.5 million for Q1 2026, up 45.91% year-over-year from $7.2 million in Q1 2025, and down 83.04% on a QoQ basis from $61.7 million in Q4 2025.
Kura Oncology (KURA) has 17 years of Accumulated Expenses data on file, last reported at $10.5 million in Q1 2026.
- Quarterly Accumulated Expenses rose 45.91% year-over-year to $10.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 million (up 45.91% YoY) and the FY2025 annual result came in at $61.7 million, up 252.39% from the prior year.
- Accumulated Expenses slipped to $10.5 million in Q1 2026 per KURA's latest filing, from $61.7 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $61.7 million in Q4 2025 and bottomed at $4.5 million in Q1 2022.
- The 5-year median for Accumulated Expenses is $9.1 million (2023), against an average of $12.5 million.
- The widest annual swing landed in 2022, when Accumulated Expenses gained 12.05%; it then soared 252.39% in 2025.
- Tracing KURA's Accumulated Expenses over 5 years: stood at $10.3 million in 2022, then increased by 27.7% to $13.2 million in 2023, then surged by 33.11% to $17.5 million in 2024, then soared by 252.39% to $61.7 million in 2025, then tumbled by 83.04% to $10.5 million in 2026.
- Per Business Quant, the three latest KURA Accumulated Expenses figures stand at $10.5 million (Q1 2026), $61.7 million (Q4 2025), and $14.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Kura Oncology | 801.92 Mn | 801.92 Mn | 18.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.47 Mn |
| Dec 31, 2025 | 61.70 Mn |
| Sep 30, 2025 | 14.60 Mn |
| Jun 30, 2025 | 10.03 Mn |
| Mar 31, 2025 | 7.17 Mn |
| Dec 31, 2024 | 17.51 Mn |
| Sep 30, 2024 | 12.48 Mn |
| Jun 30, 2024 | 8.93 Mn |
| Mar 31, 2024 | 6.06 Mn |
| Dec 31, 2023 | 13.15 Mn |
| Sep 30, 2023 | 9.07 Mn |
| Jun 30, 2023 | 6.84 Mn |
| Mar 31, 2023 | 5.07 Mn |
| Dec 31, 2022 | 10.30 Mn |
| Sep 30, 2022 | 7.97 Mn |
| Jun 30, 2022 | 5.94 Mn |
| Mar 31, 2022 | 4.49 Mn |
| Dec 31, 2021 | 7.92 Mn |
| Sep 30, 2021 | 6.44 Mn |
| Jun 30, 2021 | 5.30 Mn |
| Mar 31, 2021 | 3.86 Mn |
| Dec 31, 2020 | 7.02 Mn |
| Sep 30, 2020 | 5.01 Mn |
| Jun 30, 2020 | 3.04 Mn |
| Mar 31, 2020 | 2.09 Mn |
| Dec 31, 2019 | 3.69 Mn |
| Sep 30, 2019 | 2.86 Mn |
| Jun 30, 2019 | 2.28 Mn |
| Mar 31, 2019 | 1.57 Mn |
| Dec 31, 2018 | 3.44 Mn |
| Sep 30, 2018 | 2.08 Mn |
| Jun 30, 2018 | 1.56 Mn |
| Mar 31, 2018 | 1.05 Mn |
| Dec 31, 2017 | 2.35 Mn |
| Sep 30, 2017 | 1.65 Mn |
| Jun 30, 2017 | 1.16 Mn |
| Mar 31, 2017 | 802,000.00 |
| Dec 31, 2016 | 1.91 Mn |
| Sep 30, 2016 | 1.23 Mn |
| Jun 30, 2016 | 932,000.00 |
| Mar 31, 2016 | 569,000.00 |
| Dec 31, 2015 | 1.28 Mn |
| Sep 30, 2015 | 960,000.00 |
| Jun 30, 2015 | 1.19 Mn |
| Mar 31, 2015 | 76,000.00 |
| Dec 31, 2014 | 39,000.00 |
| Sep 30, 2014 | 22,111.00 |
| Jun 30, 2014 | 2,925.00 |
| Mar 31, 2014 | 7,000.00 |
| Dec 31, 2013 | 17,175.00 |
| Sep 30, 2013 | 3,000.00 |
| Jun 30, 2013 | 13,848.00 |
| Mar 31, 2013 | 1,500.00 |
| Dec 31, 2012 | 5,500.00 |
| Sep 30, 2012 | 1,500.00 |
| Jun 30, 2012 | 8,727.00 |
| Mar 31, 2012 | 1,500.00 |
| Dec 31, 2011 | 5,500.00 |
| Sep 30, 2011 | 7,180.00 |
| Jun 30, 2011 | 6,185.00 |
| Mar 31, 2011 | 6,324.00 |
| Dec 31, 2010 | 5,500.00 |